share_log

Atossa Therapeutics Releases Preliminary Analysis From Phase 2 Trial Of (Z)-endoxifen As Part Of I-SPY 2 Endocrine Optimization Pilot Will Be Subject Of Poster Presentation At Inaugural RISE UP Breast Cancer Conference

Benzinga ·  Oct 31 05:40

(Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 Trial

Low dose (Z)-endoxifen was well tolerated and demonstrated promising rapid activity in reducing 3-wk Ki-67 and FTV Biomarkers

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment